Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00178373 · ClinicalTrials.gov registry record · Phase 2
Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT00178373 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 96 participants.
The verdict
NCT00178373, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of modafinil with regard to reducing cancer-related fatigue in cancer patients following chemotherapy or radiation therapy. Secondarily, the effect of modafinil on cognitive dysfunction in the same population will be assessed. The researchers hypothesize that administering modafinil (PROVIGIL®) to patients experiencing fatigue following completion of cancer treatment will lead to reduction in patient fatigue and prevention of or improvement in patient cognitive dysfunction.
Interventions
- DRUG Modafinil
- DRUG sugar pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00178373
The ClinicalTrials.gov registry entry for NCT00178373 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Modafinil is the first listed.
NCT00178373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00178373 about?
NCT00178373 is a clinical study titled "Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer". The purpose of this study is to determine the efficacy of modafinil with regard to reducing cancer-related fatigue in cancer patients following chemotherapy or radiation therapy. Secondarily, the effect of modafinil on cognitive dysfunction in the same population will be assessed. The researchers h...
What is the current status of trial NCT00178373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2004-05. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00178373?
The interventions under investigation include: Modafinil (DRUG), sugar pill (DRUG).
Who is sponsoring clinical trial NCT00178373?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.